Passweg, Jakob R; Baldomero, Helen; Ansari, Marc; Arber, Caroline; Chalandon, Yves; Daskalakis, Michael; Diepold, Miriam; Diesch-Furlanetto, Tamara; Duchosal, Michel A; Gerull, Sabine; Güngör, Tayfun; Heim, Dominik; Hitz, Felicitas; Holbro, Andreas; Masouridi-Levrat, Stavroula; Nair, Gayathri; Novak, Urban; Pabst, Thomas; Renner, Christoph; Stussi, Georg; ... (2024). Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021. Hematological oncology, 42(1), e3241. Wiley 10.1002/hon.3241
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
Hematological_Oncology_-_2023_-_Passweg_-_Hematopoietic_cell_transplantation_and_cellular_therapies_in_Switzerland_.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB) |
The Swiss Blood Stem Cell Transplantation and Cellular Therapy Group (SBST) leads a mandatory national registry for all hematopoietic stem cell transplants (HCT) and cellular therapies. After 25 years, information was available for 11,226 patients receiving an HCT (4031 allogeneic and 7195 autologous), including 925 pediatric patients. We compared patient characteristics and outcome by quinquennia 1997-2001, 2002-2006, 2007-2011, 2012-2016, and 2017-2021. There were numerous changes over time. Allogeneic transplant recipients became older (median age 33.7 vs. 54.3) and had more frequently unrelated donors and reduced intensity conditioning in later quinquennia. Similarly, age increased for recipients of autologous HCT (median 48.3 vs. 59.9). We did not see a significant drop in transplant activity during the SARS-CoV-2 pandemic. Analysis of outcome showed overall survival (relative risk (RR) of death 0.664 (0.529-0.832) and progression free survival (RR 0.708 (0.577-0.870) being improved over time comparing the latest to the first quinquennium adjusting for risk factors. Non-relapse mortality decreased in recipients of allogeneic HCT (RR: 0.371 (0.270-0.509)) over time but relapse risks did not. Outcome of autologous HCT improved as well across quinquennia, this improvement was mainly due to decreased relapse risks (RR 0.681 (0.597-0.777)), possibly related to maintenance treatment or rescue treatment for relapse mainly in myeloma patients. Cellular therapies other than allogeneic or autologous HCT, particularly chimeric antigen receptor T-cells (CAR-T) treatment have started to increase after 2019, year of approval of the first commercial CAR-T product in Switzerland. Data on chimeric antigen receptor T-cell treatment are too early for comparative analyses. Detailed analyses of changes over time are presented. This study includes all HCTs, and cellular therapies, data useful for quality assurance programs, health care cost estimation and benchmarking. Between 50% and 60% of patients are long-term survivors after both types of HCT, indicating growing populations of surviving patients requiring long-term care.
Actions (login required)
 |
Edit item |